SPOTLIGHT -
EP. 1: Universal Screening for BRCA1 and BRCA2 Mutations
EP. 2: Prophylactic Oophorectomy for Reducing Ovarian Cancer Risk
EP. 3: Timing of Oophorectomy in Ovarian Cancer
EP. 4: Neoadjuvant Chemotherapy for Ovarian Cancer
EP. 5: Cytoreductive Surgery for Ovarian Cancer
EP. 6: Goal of Surgery in Ovarian Cancer
EP. 7: Chemotherapy Regimens for Ovarian Cancer
EP. 8: Treatment Options in Ovarian Cancer
EP. 9: Antiangiogenic Agents in Ovarian Cancer
EP. 10: Intraperitoneal Chemotherapy in Ovarian Cancer
EP. 11: CA-125 Testing in Ovarian Cancer
EP. 12: Platinum Resistance in Ovarian Cancer
EP. 13: Bevacizumab in Ovarian Cancer
EP. 14: Promising Treatments in Ovarian Cancer
EP. 15: Cervical Cancer Screening and Prevention
EP. 16: Bevacizumab in Recurrent Metastatic Cervical Cancer
EP. 17: Emerging Therapies in Cervical Cancer
EP. 18: Challenges for the Future of Gynecologic Cancers
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
